Court orders Dr. Reddy's to temporarily halt sales of its purple Nexium copy

In the second bit of bad news for Dr. Reddy's Laboratories ($RDY) in days, the company said on Tuesday that a U.S. federal court had temporarily barred sales of its generic of AstraZeneca's ($AZN) blockbuster heartburn drug Nexium in the U.S., Reuters reports. The order came after the U.K. drugmaker objected to the Indian company's product using the purple color that has come to distinguish AstraZeneca's branded drug. Dr. Reddy's launched its generic Nexium in September after weeks of delay because it had to move production to a different plant after the FDA uncovered GMP issues at the facility where it would be made. The Indian drugmaker said on Friday that the FDA had sent it a warning letter for three of its plants. Story | More

Suggested Articles

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

The $520 million investment includes $230 million for AZ's Dunkirk, France manufacturing site dedicated to inhalers and $275 million for R&D.

Manufacturing issues have caused GlaxoSmithKline to halt production and distribution of Excedrin, which has led to outages at some pharmacies.